Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Investment Securities (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Gains from Investment Securities for 8 consecutive years, with $74915.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Investment Securities fell 14.87% year-over-year to $74915.0; the TTM value through Mar 2026 reached $74915.0, down 14.87%, while the annual FY2025 figure was $9.0 million, N/A changed from the prior year.
  • Gains from Investment Securities hit $74915.0 in Q1 2026 for Kymera Therapeutics, up from -$16.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.6 million in Q3 2025 and bottomed at -$49.7 million in Q4 2023.
  • Average Gains from Investment Securities over 5 years is -$4.1 million, with a median of $216289.0 recorded in 2023.
  • Year-over-year, Gains from Investment Securities crashed 99.51% in 2022 and then skyrocketed 3673.82% in 2024.
  • Kymera Therapeutics' Gains from Investment Securities stood at $2.8 million in 2022, then plummeted by 1876.5% to -$49.7 million in 2023, then skyrocketed by 61.47% to -$19.2 million in 2024, then increased by 16.53% to -$16.0 million in 2025, then skyrocketed by 100.47% to $74915.0 in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $74915.0, -$16.0 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.